No Data
No Data
CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference
Marker Therapeutics (MRKR) Receives a Buy From Canaccord Genuity
WBB Securities Initiates Marker Therapeutics(MRKR.US) With Buy Rating, Announces Target Price $12.5
Express News | WBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target
Marker Therapeutics Reports FY24 EPS ($1.19) Vs ($1.59) Last Year